Tianjin Pharmaceutical Da Re Tang Group Corp Ltd: Financial Highlights and Announcements
Tianjin Pharmaceutical Da Re Tang Group Corp Ltd, a prominent player in the healthcare sector, has recently made several key announcements regarding its financial performance and strategic developments. The company, which operates primarily in the pharmaceutical industry, is based in Tianjin, China, and is listed on the Shanghai Stock Exchange.
Financial Performance and Cash Flow Insights
In a recent update, Tianjin Pharmaceutical Da Re Tang Group Corp Ltd addressed investor queries regarding discrepancies in its 2024 financial statements. The company reported a net borrowing of 7 billion USD, with cash flow statements showing 12 billion USD in loans obtained and 5 billion USD repaid. However, the balance sheet reflected only 0.2 billion USD in combined short-term and long-term loans. The company clarified that this discrepancy was primarily due to transactions involving Tianjin Zhongxin Pharmaceutical Co., Ltd. During 2024, the company completed a full equity investment in Tianjin Zhongxin Pharmaceutical Co., Ltd., which subsequently became a joint venture. As a result, Tianjin Zhongxin Pharmaceutical Co., Ltd. was no longer included in the consolidated financial statements by the end of 2024.
Estimated Results for H1 2025
The company has also announced its estimated results for the first half of 2025. Tianjin Pharmaceutical Da Re Tang Group Corp Ltd anticipates a significant increase in net profit, projecting a range of 18.40 billion to 20.00 billion USD. This represents a substantial year-over-year growth of 180.00% to 204.00%. The forecast is based on several factors, including the sale of a 12% stake in its joint venture, Tianjin Shrek Pharmaceuticals Ltd., to Haleon (China) Ltd. and HaleonCHSARL, resulting in a disposal gain of 15.4 billion USD and a post-tax net profit of 13.1 billion USD.
Strategic Developments and Business Overview
The company’s strategic focus remains on its core business areas, including the development and commercialization of traditional Chinese medicines, western medicines, and healthcare products. Tianjin Pharmaceutical Da Re Tang Group Corp Ltd is renowned for its well-established brands such as Da Re Tang, Longshun Rong, Le Ren Tang, and Jing Wan Hong, which are recognized as Chinese cultural heritage brands. The company holds 14 non-material cultural heritage representative projects, with five at the national level, underscoring its commitment to preserving traditional Chinese medicine practices.
As Tianjin Pharmaceutical Da Re Tang Group Corp Ltd continues to expand its market presence and enhance its product offerings, it remains a key player in the pharmaceutical industry, with a strong emphasis on innovation and cultural heritage.